Developing a new treatment method for liver cancer using specialized drug delivery systems.
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy
This study is exploring a new way to treat liver cancer by using a special delivery system to combine two drugs that work together to target stubborn cancer cells, which could lead to better treatment options for patients facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10912688 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for hepatocellular carcinoma (HCC), a type of liver cancer that is becoming more common but has limited chemotherapy options. The approach involves creating a polymeric micelle-based drug delivery system that combines two drugs: cyclopamine, which targets cancer stem cells, and paclitaxel, a chemotherapy agent. By using this dual-drug strategy, the research aims to overcome drug resistance and effectively eliminate both cancer stem cells and rapidly dividing tumor cells. Patients may benefit from a more effective treatment that addresses the challenges of recurrence and resistance associated with HCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who have limited treatment options.
Not a fit: Patients with early-stage liver cancer or those who do not have hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for liver cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using combination therapies for cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Li, Chun — University of Tx Md Anderson Can Ctr
- Study coordinator: Li, Chun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.